![](https://agilecapitalmarkets.com/wp-content/uploads/2022/10/cardiawave.webp)
Cardiawave announces the authorization by the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a new clinical study in France
Paris, France, May 2, 2022 – Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a new clinical study in France.